PL2147122T3 - Enzymatyczna terapia przeciwnowotworowa - Google Patents

Enzymatyczna terapia przeciwnowotworowa

Info

Publication number
PL2147122T3
PL2147122T3 PL08754910T PL08754910T PL2147122T3 PL 2147122 T3 PL2147122 T3 PL 2147122T3 PL 08754910 T PL08754910 T PL 08754910T PL 08754910 T PL08754910 T PL 08754910T PL 2147122 T3 PL2147122 T3 PL 2147122T3
Authority
PL
Poland
Prior art keywords
anticancer therapy
enzymatic
enzymatic anticancer
therapy
anticancer
Prior art date
Application number
PL08754910T
Other languages
English (en)
Polish (pl)
Inventor
David R Filpula
Puja Sapra
Original Assignee
Leadiant Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadiant Biosciences Ltd filed Critical Leadiant Biosciences Ltd
Publication of PL2147122T3 publication Critical patent/PL2147122T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL08754910T 2007-04-20 2008-04-18 Enzymatyczna terapia przeciwnowotworowa PL2147122T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91303907P 2007-04-20 2007-04-20
EP08754910.1A EP2147122B1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy
PCT/US2008/060733 WO2008131163A1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy

Publications (1)

Publication Number Publication Date
PL2147122T3 true PL2147122T3 (pl) 2015-05-29

Family

ID=39875909

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08754910T PL2147122T3 (pl) 2007-04-20 2008-04-18 Enzymatyczna terapia przeciwnowotworowa

Country Status (19)

Country Link
US (1) US8741283B2 (enExample)
EP (1) EP2147122B1 (enExample)
JP (1) JP5595904B2 (enExample)
KR (1) KR101540296B1 (enExample)
CN (1) CN101680039B (enExample)
BR (1) BRPI0810384B8 (enExample)
CA (1) CA2684749C (enExample)
CY (1) CY1117000T1 (enExample)
DK (1) DK2147122T3 (enExample)
ES (1) ES2507508T3 (enExample)
HR (1) HRP20140947T1 (enExample)
IL (1) IL201593A (enExample)
MX (1) MX2009011320A (enExample)
NZ (1) NZ580980A (enExample)
PL (1) PL2147122T3 (enExample)
PT (1) PT2147122E (enExample)
SI (1) SI2147122T1 (enExample)
TW (1) TWI486169B (enExample)
WO (1) WO2008131163A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2503765T3 (es) 2004-11-12 2014-10-07 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
HRP20160482T1 (hr) 2007-04-20 2016-06-03 Sigma-Tau Rare Disease Ltd Stabilna rekombinantna adenozin deaminaza
EP2670850B1 (en) * 2011-02-03 2016-10-26 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
WO2016191283A2 (en) * 2015-05-22 2016-12-01 University Of Houston System Enzymatic immunomodulation of solid tumors and user thereof
CA3056071A1 (en) * 2016-03-11 2017-09-14 University Of Louisville Research Foundation, Inc. Methods and compositions for treating tumors
JP2020516654A (ja) 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
US10993967B2 (en) 2018-10-17 2021-05-04 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2023086931A2 (en) * 2021-11-12 2023-05-19 Georgia Tech Research Corporation Adenosine deaminase 1 compositions and methods for using same
US20240250753A1 (en) * 2022-10-10 2024-07-25 Berkeley Marine Robotics Inc. Ship Hull Inspection using a Swarm of Unmanned Underwater Vehicles equipped with Wireless Laser Systems

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346823A (en) * 1984-05-29 1994-09-13 Genencor, Inc. Subtilisin modifications to enhance oxidative stability
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999030727A1 (en) * 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6824766B2 (en) * 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6333396B1 (en) * 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US20020088017A1 (en) * 1999-04-28 2002-07-04 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
AU7868400A (en) 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
WO2002077233A2 (en) * 2000-11-08 2002-10-03 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 METHODS AND COMPOSITIONS OF HUMAN PROTEINS AND USES THEREOF
US20040105839A1 (en) * 2001-11-28 2004-06-03 Myung-Ok Park Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
CA2470104C (en) 2001-12-12 2015-01-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US20040175804A1 (en) * 2003-03-04 2004-09-09 Skonezny Paul M. Process for preparing dideoxyinosine using adenosine deaminase enzyme
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7601798B2 (en) * 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
JP2010500963A (ja) 2006-06-21 2010-01-14 エンゾン ファーマスーティカルズ インコーポレイテッド 安定化タンパク質
JP2010503705A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド ヒンダードエステル系の生分解性リンカーを有するポリアルキレンオキサイド
EP2117528A4 (en) * 2006-12-29 2013-01-02 Sigma Tau Rare Diseases S A USE OF ADENOSINE DEAMINASE FOR THE TREATMENT OF LUNG DISEASES
HRP20160482T1 (hr) 2007-04-20 2016-06-03 Sigma-Tau Rare Disease Ltd Stabilna rekombinantna adenozin deaminaza

Also Published As

Publication number Publication date
DK2147122T3 (da) 2014-10-13
CA2684749A1 (en) 2008-10-30
EP2147122A1 (en) 2010-01-27
ES2507508T3 (es) 2014-10-15
TWI486169B (zh) 2015-06-01
NZ580980A (en) 2012-04-27
JP5595904B2 (ja) 2014-09-24
CN101680039A (zh) 2010-03-24
SI2147122T1 (sl) 2015-01-30
PT2147122E (pt) 2014-10-15
KR101540296B1 (ko) 2015-07-31
US8741283B2 (en) 2014-06-03
BRPI0810384A2 (pt) 2014-11-04
JP2010524968A (ja) 2010-07-22
TW200902051A (en) 2009-01-16
WO2008131163A1 (en) 2008-10-30
BRPI0810384B8 (pt) 2021-05-25
KR20090130108A (ko) 2009-12-17
US20090047270A1 (en) 2009-02-19
EP2147122A4 (en) 2010-11-17
EP2147122B1 (en) 2014-07-16
HRP20140947T1 (hr) 2015-02-13
CN101680039B (zh) 2016-08-24
CY1117000T1 (el) 2017-04-05
RU2009142817A (ru) 2011-05-27
WO2008131163A8 (en) 2010-01-28
IL201593A0 (en) 2010-05-31
MX2009011320A (es) 2009-12-15
CA2684749C (en) 2016-06-21
BRPI0810384B1 (pt) 2021-02-02
AU2008242791A1 (en) 2008-10-30
IL201593A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
IL206654A0 (en) Combination therapy
GB0712494D0 (en) Substrate reduction therapy
GB0715346D0 (en) Stimulator
IL199992A0 (en) Combination therapy
PT2147122E (pt) Terapia enzimática antitumoral
EP2054061A4 (en) COMBINATION THERAPY
EP2334695A4 (en) THERAPEUTIC RIBONUCLEASES
GB0719518D0 (en) Therapy
EP2211863A4 (en) COMBINATION THERAPY
IL208001A0 (en) Improved anticancer treatments
GB0700284D0 (en) Combination therapy
GB0803948D0 (en) Combination therapy
GB0716072D0 (en) Therapy
GB0700635D0 (en) Therapy
GB0707429D0 (en) HIV Therapy
GB0710043D0 (en) Anticancer treatments
GB0708693D0 (en) Anticancer treatments
GB0705917D0 (en) Therapy
GB0703963D0 (en) Therapy
AU2008903284A0 (en) Combination therapy
HK1140958A (en) Combination therapy
GB0813292D0 (en) Therapy
GB0812659D0 (en) Therapy
AU2008902139A0 (en) HLST Therapy
AU2008902090A0 (en) Cancer Therapy